When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Last reviewed: 16 Mar 2025
Last updated: 24 Oct 2024

Summary

Definition

History and exam

Key diagnostic factors

  • age 20 to 50 years
  • female sex
  • dyspnoea
  • accentuated pulmonic component (P2) to the second heart sound
  • tricuspid regurgitation murmur
  • family history

Other diagnostic factors

  • fatigue
  • peripheral oedema
  • cyanosis
  • stimulant use
  • syncope
  • chest pain
  • near syncope
  • early diastolic, high-pitched murmur in the pulmonary area
  • jugular vein distension

Risk factors

  • family history
  • female sex
  • bone morphogenetic protein receptor type 2 (BMPR2) mutations
  • appetite suppressants
  • drugs and toxins

Diagnostic investigations

1st investigations to order

  • chest x-ray
  • ECG
  • transthoracic Doppler echocardiography
  • right heart catheterisation
  • antinuclear antibodies (ANA)
  • pulmonary function tests
  • arterial blood gas (ABG)
  • nocturnal oximetry
  • ventilation-perfusion (V/Q) scintigraphy
  • 6-minute walk test
  • B-type natriuretic peptide (BNP) or N-terminal proBNP (NT-proBNP)
  • FBC
  • LFTs
  • thyroid function tests
  • HIV serology

Investigations to consider

  • high-resolution chest CT scan ± CT pulmonary angiography
  • cardiac MRI
  • vasodilator testing with inhaled nitric oxide, inhaled iloprost, or intravenous epoprostenol

Treatment algorithm

Contributors

Authors

Muhammad Sameed, MD

Director Advance Lung Disease Program

Department of Pulmonary & Critical Care Medicine

Assistant professor of Medicine

Thomas Jefferson University Hospital - Einstein Health

Philadelphia

PA

Disclosures

MS declares that he has no competing interests.

Gustavo A. Heresi, MD, MS
Gustavo A. Heresi

Director, Pulmonary Vascular and CTEPH Program

Department of Pulmonary and Critical Care Medicine

Respiratory Institute

Cleveland Clinic

Cleveland

OH

Disclosures

GAH has received speaking and advisory board fees from Bayer Healthcare, the manufacturer of riociguat.

Acknowledgements

Dr Muhammad Sameed and Dr Gustavo A. Heresi would like to gratefully acknowledge Dr Raed A. Dweik, a previous contributor to this topic.

Disclosures

RAD declares that he has no competing interests.

Peer reviewers

Michael J. Krowka, MD

Division of Pulmonary and Critical Care Medicine

Mayo Clinic College of Medicine

Rochester

MN

Disclosures

MJK declares that he has no competing interests.

Charlie Elliot, MB ChB, MRCP

Consultant Physician in Respiratory and General Internal Medicine

Sheffield Pulmonary Vascular Disease Unit

Royal Hallamshire Hospital

Sheffield

UK

Disclosures

CE has received reimbursement for attending several conferences as well as lecture fees from Actelion Pharmaceuticals, GSK, and Bayer.

Maria Giovanna Triveri, MD, PhD

​​Assistant Professor of Cardiology,

Medical Director of the Pulmonary Hypertension Program

Icahn School of Medicine at Mount Sinai Hospital

New York

NY

Disclosures

MGT has participated on Advisory Boards of Bayer and Actelion and received financial compensation for attendance.

Use of this content is subject to our disclaimer